Skip to main content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

CASPIAN: Durvalumab addition boosts SCLC survival

IV drip 2

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

Elevated cardiovascular risk seen in survivors of most common cancers

New Content Item

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

Combining local and systemic therapy improves survival for advanced NSCLC

Lung radiographs_operation theatre

In patients with stage IV non-small-cell lung cancer, the addition of surgical resection or external beam radiotherapy/thermal ablation to systemic therapy increases overall survival versus systemic therapy alone, suggests a comparative effectiveness study.

Latest headlines

13-09-2019 | Non-small cell lung cancer | WCLC 2019 | News

IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

The final analysis of the IMpower131 trial reveals an overall survival benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous non-small-cell lung cancer who strongly express PD-L1.

12-09-2019 | Non-small cell lung cancer | WCLC 2019 | News

LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

12-09-2019 | Screening | WCLC 2019 | News

microRNA plus LDCT guides optimal lung cancer screening intensity

Combining low-dose computed tomography with a blood microRNA test can help establish the most appropriate screening frequency among heavy smokers at risk for lung cancer, study data show.

In depth

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

28-01-2019 | Immunotherapy | At a glance | Article

Gut microbiota and immunotherapy response: A round-up of the trials

A round-up of the key studies – all published in Science – that have investigated the association between the gut microbiome and response to immune checkpoint inhibitors.

Image Credits